Impact of Metformin on Immunity

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether metformin (MET) can improve the immune response to the pneumococcal conjugate vaccine (PCV-13) in older adults.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Treatments: Metformin

Criteria

Inclusion Criteria:

1. Age 63 to 89 years of age

2. No history of pneumococcal vaccinations

3. Able to take oral medications

4. Able to provide informed consent

5. Not currently taking metformin

Exclusion Criteria:

1. Previous vaccination with any pneumococcal vaccine

2. Metformin within the last 6 months

3. Contraindication for PCV13

4. History of severe adverse reaction associated with any vaccine component

5. Residence in long-term care facility

6. Diagnosis of diabetes (diagnosis of pre-diabetes okay)

7. Chronic renal disease (or eGFR <50 mL/min) or renal failure (defined as receipt of renal dialysis or transplant) or nephrotic syndrome

8. History of adverse reaction or contraindications associated with metformin

9. Recent history or plan for radiocontrast

10. Self-reported dementia or severe cognitive impairment

11. Receipt of blood products within 6 months before enrollment

12. History of heart disease (New York Heart Classification greater than class II; more than non-specific ST-T wave changes on the ECG)

13. History of chronic obstructive pulmonary disease

14. Poorly controlled blood pressure (systolic BP>160, diastolic BP>90 mmHg)

15. History of an immunodeficiency

16. Use of use of investigational products, antibiotics, probiotics, or systemic immunosuppressive therapy (systemic steroids) within 1 month of study start; patients who are taking these medications chronically, with no expected discontinuation during the study period would not be considered ineligible.

17. Treatment with anticoagulants (warfarin)

18. Donated blood within the last 2 months

19. Subject is considered unsuitable for the study in the opinion of the investigator for any other reason